Ipsen Global - A Biopharmaceutical Company | Innovation for Patient Care

WHO WE ARE

As a mid-sized global biopharmaceutical company, Ipsen improves patients’ lives through research, innovation and the development of transformative medicines in Oncology, Rare Disease and Neuroscience.

WHAT WE DO

WHAT WE DO

Improving people’s lives and health outcomes by focusing on areas of high unmet medical need, we are accelerating our momentum and rapidly boosting our pipeline to bring the full potential of our innovative medicines to patients.

Author Image

Our strategy has been instrumental in making us a leader in our field. Our global presence, resources, expertise and strong track record commercializing our medicines are resulting in a real impact for people living with high unmet medical needs. We’re leveraging the full force of Ipsen’s infrastructure, innovation and passion to develop new therapies and valuable collaborations.

David Loew

CEO

 

PATIENTS

Putting patients at the heart of our work

Our commitment to improving the lives and medical outcomes of patients is the driving force behind every decision made at Ipsen. We believe in working with patients, for patients, listening to their needs and involving their insights in the entire.

RESPONSIBILITY

RESPONSIBILITY

Shaping a more sustainable future

Ipsen is dedicated to safeguarding and preserving our planet. The Generation Ipsen ESG responsibility strategy lays out ambitious goals for the company in each of four pillars: Environment, Patients, People and Governance.

Careers at Ipsen

Ipsen offers a multitude of exciting opportunities for talented and motivated people in careers ranging from medial and clinical research to sales, marketing, finance, IT, HR and legal services. We are committed to providing our employees with a workplace that is welcoming, challenging and inclusive.

Discover trending stories

31 May 2024 1 mins read

Our 2023 Integrated Annual Report is live!

In 2023, we entered the next phase of our journey of growth and innovation, reinforcing our position as a leading mid-sized biopharmaceutical company. With a sharp focus on our three therapy areas of Oncology, Rare Diseases, and Neuroscience, we achieved total sales of €3,128 m.

29 May 2024 1 mins read

Together, we can improve the lives of people living with kidney cancer

Together for Kidney Cancer is a global disease awareness initiative funded by Ipsen aiming to raise awareness of the reality of people’s experiences living with kidney cancer and the importance of shared decision making to inform better care outcomes.

22 May 2024 3 mins read

Ipsen’s Commitment to Biodiversity  

Biodiversity encompasses the rich array of species and ecosystems vital for our planet’s health. Yet, human activities have endangered this diversity, jeopardizing not only various species but also our daily lives. Biodiversity is crucial for human health, providing essential services such as pollin

20 May 2024 4 mins read

Exploring life and parenthood with Primary Biliary Cholangitis 

Sandra Silvestri, Executive Vice President & Chief Medical Officer at Ipsen, reflects on the challenges women living with primary biliary cholangitis (PBC) face and why we have big dreams of a better future for PBC.

20 May 2024 4 mins read

Improving Diversity in Research and Development to Drive Health Equity

To mark World Clinical Trials Day, we sat down with Christelle Huguet, Executive Vice President, Head of R&D at Ipsen to explore the importance of diversity from all sides of the research and development process, as we accelerate innovation.  

14 May 2024 2 mins read

Progressive Familial Intrahepatic Cholestasis (PFIC): Liver experts discuss early diagnosis and management 

Progressive Familial Intrahepatic Cholestasis (PFIC) is a rare liver disease that can pose significant challenges, particularly in young children1, but the good news is that there are growing opportunities to manage the disease, slow its progression and improve outcomes.  

29 April 2024 0 mins read

2024 Annual General Meeting

A replay with complete presentation and Q&A session will be made available soon after the Annual General Meeting.

22 April 2024 3 mins read

Navigating Proactive Sustainability in Pharma R&D and Partnering

In March, we were proud to see Florence Dal Degan, Senior Director of External Innovation, participate in a panel discussion with different stakeholders, from consulting firms, pharma companies, investors to startups at BioEurope Spring entitled “Towards a Greener Globe: Biopharma’s Path to Sustaina

19 April 2024 0 mins read

Q1 2024 sales update

The Q1 2024 sales announcement will be published on April 24, 2024 at 7am CET. Find out more and register for the conference call for investors and analysts.

10 April 2024 3 mins read

Going on a PBC journey together

At seventy-one-years young, Gill, a devoted mother and grandmother from Nottinghamshire, loves spending time with her grandchildren and gardening. She also has a real passion for her volunteering work, to raise awareness of the ‘invisible, and isolating disease she has…